Drug-induced pleural diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


The problem of differential diagnosis of pleural diseases involves a large number of pathological conditions causing its damage, which physicians are not aware about. Drug-induced (DI) lesion occupies a special place in the structure of pleural diseases, both due to the relatively low prevalence and due to insufficient awareness of doctors about the presence of such adverse reactions in drugs. At the same time, thanks to modern information about the morphology, physiology and pathophysiology of the pleura and pleural cavities, the diagnosis and treatment of pleural diseases are becoming more and more effective. The article presents the data of modern literature and electronic databases of The Drug-Induced Respiratory Disease Website about DI lesions of the pleura. This review provides information about the main types of DI lesions of the pleura and the scope of drugs that cause these reactions. Ultimately, doctors’ awareness of drug-induced pleural diseases can ensure timely diagnosis of these conditions, correct therapy, and ultimately improve the quality of medical care.

Full Text

Restricted Access

About the authors

Olga D. Ostroumova

Russian Medical Academy of Continuous Professional Education; Sechenov First Moscow State Medical Univesity (Sechenov University)

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0002-0795-8225
SPIN-code: 3910-6585
Scopus Author ID: 7004067629
ResearcherId: M-9553-2014

MD, Dr. Sci. (Med.), Professor
Russian Federation, 2/1, bld.1 Barrikadnaya str., Moscow, 125993, Russia

Natalya S. Smetneva

Moscow Medical University “Reaviz”; The Russian National Research Medical University named after N.I. Pirogov; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: smetneva_85@mail.ru
ORCID iD: 0000-0002-2131-387X
SPIN-code: 3124-2726
Scopus Author ID: 57204853668

Associate Professor

Russian Federation, 2/1, bld.1 Barrikadnaya St., Moscow, 125993; Moscow; Moscow

Valeriya A. De

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: devaleria97@mail.ru
ORCID iD: 0000-0002-3900-758X
SPIN-code: 1817-6115
Scopus Author ID: 57209973626
Russian Federation, 2/1, bld.1 Barrikadnaya str., Moscow, 125993


  1. Chuchalin AG, Shojhet JaN, Abakumov MM. Pleural diseases. Moscow: Atmosphera; 2018. 276 p. (In Russ.).
  2. The Drug-Induced Respiratory Disease Website [Internet]. Camus Ph. Available from: http://www.pneumotox.com. Accessed: Nov 27, 2011.
  3. Decologne N, Kolb M, Margetts PJ, et al. TGF-β1 induces progressive pleural scarring and subpleural fibrosis. Journal of Immunology. 2007;179(9):6043–6051. doi: 10.4049/jimmunol.179.9.6043
  4. Lin CM, Rhiannon JJ, Chan ED. Drug-induced pleural disease. Adverse Drug Reaction Bulletin. 2013;281(1):1083–1086. doi: 10.1097/FAD.0b013e3283651c4f
  5. Moschos C, Kalomenidis I. Drug related pleural disease. Pleural Bulletin, Turk Toraks Denergi. 2010;4:8–16.
  6. Allen TC, Suster S. Pathology of the Pleura and Mediastinum. Switzerland: Springer; 2018. 493 p. doi: 10.1007/978-3-319-66796-6_4299
  7. Chen JR, Yang YC. Spontaneous pneumothorax after intensive chemotherapy in endometrial cancer: a rare complication. Taiwan J Obstet Gynecol. 2014;53(2):245–247. doi: 10.1016/j.tjog.2013.09.002
  8. Bazan F, Vollmer I, Gayete A. Chemotherapy-induced secondary pneumothorax. Archivos de Bronconeumologia. 2014;50(1):44. doi: 10.1016/j.arbres.2013.06.007
  9. Jung JI, Choi JE, Hahn ST, et al. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol. 2002;178(2):475–480. doi: 10.2214/ajr.178.2.1780475
  10. Amano Y, Tajika K, Mizuki T, et al. All-trans retinoic acid syndrome: chest CT assessment. Eur Radiol. 2001;11(8):1516–1517. doi: 10.1007/s003300000776
  11. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;15;92(8):2712–2718. doi: 10.1182/blood.V92.8.2712
  12. Sharma S, Jagdev S, Coleman RE, et al. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer. 1999;81(6):1037–1041. doi: 10.1038/sj.bjc.6690804
  13. Beynat-Mouterde C, Beltramo G, Lezmi G, et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. European Respiratory Journal. 2014;44(2):523–527. doi: 10.1183/09031936.00214713
  14. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide Toxicity. Drugs. 1991;42(5):781–795. doi: 10.2165/00003495-199142050-00005
  15. Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol. 2015;90(4):E66–E72. doi: 10.1002/ajh.23938
  16. Gennatas S, Stanway SJ, Thomas R, et al. Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. BMC Cancer. 2013;13(1):1–4. doi: 10.1186/1471-2407-13-207
  17. Brunner AM, Costa DB, Heist RS, et al. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. Journal of Thoracic Oncology. 2013;8(11):1434–1437. doi: 10.1097/JTO.0b013e3182a47162
  18. Maral S, Bakanay SM, Kucuksahin O, et al. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib. J Oncol Pharm Pract. 2020;26(3):738–741. doi: 10.1177/1078155219863469
  19. Shen AQ, Wilson NM, Gleason SL, et al. Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview. Therapeutic advances in hematology. 2014;5(1):13–17. doi: 10.1177/2040620713510481
  20. Nakano K, Motoi N, Tomomatsu J, et al. Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis. BMC Cancer. 2016;16(1):1–7. doi: 10.1186/s12885-016-2786-z
  21. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. Journal of Clinical Oncology. 1989;7(1):7–20. doi: 10.1200/JCO.1989.7.1.7
  22. Dedov II. Bromokriptinu 50 let. Vestnik Rossiyskoy akademii nauk. 2019;89(11):1137–1142. (In Russ.). doi: 10.31857/S0869-587389111137-1142
  23. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Movement Disorders. 2009;24(1):129–133. doi: 10.1002/mds.22385
  24. Müller T., Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin Neuropharmacol. 2003;26(3):109–111. doi: 10.1097/00002826-200305000-00001
  25. Champagne S, Coste E, Peyrière H, et al. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases. Ann Pharmacother. 1999;33(10):1050–1054. doi: 10.1345/aph.18461
  26. Comet R, Domingo C, Such JJ, et al. Pleuropulmonary disease as a side-effect of treatment with bromocriptine. Respir Med. 1998;92(9):1172–1174. doi: 10.1016/s0954-6111(98)90415-2
  27. Hillerdal G, Lee J, Blomkvist A, et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J. 1997;10(12):2711–2715. doi: 10.1183/09031936.97.10122711
  28. Vergeret J, Barat M, Taytard A, et al. Pleuropulmonary fibrosis and bromocriptine. Sem Hop. 1984;60(11):741–744. (In French.)
  29. Besser GM, Wass JA. Pleuropulmonary shadows on bromocriptine. Lancet. 1981;1(8215):323. doi: 10.1016/s0140-6736(81)91927-9
  30. Tornling G, Unge G, Axelsson G, et al. Pleuropulmonary reactions in patients on bromocriptine treatment. Eur J Respir Dis. 1986;68(1):35–38.
  31. Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest. 1988;94(5):1034–1036. doi: 10.1378/chest.94.5.1034
  32. McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med. 1988;148(10):2231–2236. doi: 10.1001/archinte.1988.00380100089019
  33. Melmed S, Braunstein GD. Bromocriptine and pleuropulmonary disease. Arch Intern Med. 1989;149(2):258–259. doi: 10.1001/archinte.1989.00390020008002
  34. Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, et al. Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline. Archivos de Bronconeumologia. 2009;45(2):100–102. (In Spanish.) doi: 10.1016/j.arbres.2008.01.003
  35. Muñoz-Morente A, Garcia-Trujillo L, Soto-Hurtado EJ, et al. Recurrent nerve paralysis and pleural effusion due to cabergoline. Revista de Neurologia. 2008;46(6):382–383. (In Spanish.) doi: 10.33588/rn.4606.2008116
  36. Hawatmeh A, Thawabi M, Jmeian A, et al. Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: A case report and literature review. J Nat Sci Biol Med. 2017;8(1):130–133. doi: 10.4103/0976-9668.198345
  37. Yaşar Bilge NS, Gönüllü E, Kaşifoğlu T, et al. Amiodarone-induced pleural fluid is not always accompanied by a risk factor. Anadolu Kardiyol Derg. 2012;12(3):281–282. doi: 10.5152/akd.2012.081
  38. Uong V, Nugent K, Alalawi R, et al. Amiodarone-induced loculated pleural effusion: case report and review of the literature. Pharmacotherapy. 2010;30(2):218. doi: 10.1592/phco.30.2.218
  39. Gonzalez-Rothi RJ, Hannan SE, Hood CI, et al. Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions. Chest. 1987;92(1):179–182. doi: 10.1378/chest.92.1.179
  40. Vernhet H, Bousquet C, Durand G, et al. Reversible amiodarone-induced lung disease: HRCT findings. Eur Radiol. 2001;11(9):1697–1703. doi: 10.1007/s003300000809
  41. Fakhro AM, Ritchie RF, Lown B. Lupus-like syndrome induced by procainamide. Am J Cardiol. 1967;20(3):367–373. doi: 10.1016/0002-9149(67)90060-4
  42. Stanislav SW, Gonzalez-Blanco M. Papular rash and bilateral pleural effusion associated with clozapine. Annals of Pharmacotherapy. 1999;33(9):1008–1009. doi: 10.1345/aph.19038
  43. Bullington W, Sahn SA, Judson MA. Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature. Am J Med Sci. 2007;333(5):290–292. doi: 10.1097/MAJ.0b013e31805339ae
  44. Adoni A, Adatto-Levy R, Mogle P, et al. Postoperative pleural effusion caused by dextran. Int J Gynaecol Obstet. 1980;18(4):243–244. doi: 10.1002/j.1879-3479.1980.tb00488.x
  45. Roden S, Juvin K, Homasson JP, et al. An uncommon etiology of isolated pleural effusion. The ovarian hyperstimulation syndrome. Chest. 2000;118(1):256–258. doi: 10.1378/chest.118.1.256
  46. Davis JW, Jones LS. Pleural effusion: an uncommon manifestation of nitrofurantoin-induced pulmonary injury. Respiratory Medicine Case Reports. 2016;19:65–67. doi: 10.1016/j.rmcr.2016.07.009
  47. Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med. 2004;25(1):141–153. doi: 10.1016/s0272-5231(03)00125-4
  48. Chen YW, Chen YC, Wu CJ, et al. Massive bilateral pleural effusion associated with use of pioglitazone. Clin Ther. 2008;30(8):1485–1489. doi: 10.1016/j.clinthera.2008.08.003
  49. Tisdale JE, Miller DA. Drug-Induced Diseases: Prevention, Detection and Management. 3rd ed. American Society of Health-Systems Pharmacists. USA: Bethesda; 2018. 1400 p.
  50. Smith 2nd JW. Tolerability and side-effect profile of rhIL-11. Oncology (Williston Park, NY). 2000;14(9 Suppl 8):41–47.
  51. Antony VB. Drug-induced pleural disease. Clin Chest Med. 1998;19(2):331–340. doi: 10.1016/s0272-5231(05)70080-0
  52. Brixey AG, Light RW. Pleural effusions due to dasatinib. Current Opinion in Pulmonary Medicine. 2010;16(4):351–356. doi: 10.1097/mcp.0b013e328338c486
  53. Jablonskij PK, Petrov AS, Pishhik VG, et al. Spontaneous pneumothorax. Saint Petersburg: St. Petersburg University Publ.; 2013. 42 p. (In Russ.)
  54. Skol’skaja OJu, Tarasova LN, Vladimirova SG, et al. Prognostic risk factors of ATRA-syndrome in the treatment of acute promyelocytic leukemia. Klinicheskaja laboratornaja diagnostika. 2012;(10):44–47. (In Russ.)
  55. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi: 10.1038/clpt.1981.154
  56. Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateka. 2020;27(6):113–126. (In Russ.). doi: 10.18565/pharmateca.2020.6.113-26
  57. Vesanoid. Eapteka.ru [Internet] Available from: https://www.eapteka.ru/goods/drugs/oncology/vesanoid_khoffmann_lya_rosh/. Accessed: Nov 27, 2011.
  58. Savchenko VG, Parovichnikova EN, Afanas’ev BV, et al. National clinical guidelines for the diagnosis and treatment of acute myeloid leukemia in adults. Gematologija i transfuziologija. 2014;59(S2):64. (In Russ.)

Supplementary files

There are no supplementary files to display.

Copyright (c) 2021 Ostroumova O.D., Smetneva N.S., De V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies